However, despite these advances, immunotherapy has shown limited efficacy in hormone receptor-positive (HR+) breast cancers, likely due to their lower tumor mutational burden and immunosuppressive microenvironment [50,51,52]. Here, NR4A1 is linked to breast cancer.